Kristen J. Pierce

1.3k total citations
33 papers, 1.0k citations indexed

About

Kristen J. Pierce is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kristen J. Pierce has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kristen J. Pierce's work include Cancer Treatment and Pharmacology (12 papers), Colorectal Cancer Treatments and Studies (8 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Kristen J. Pierce is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Colorectal Cancer Treatments and Studies (8 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). Kristen J. Pierce collaborates with scholars based in United States, Italy and Spain. Kristen J. Pierce's co-authors include Brett E. Houk, Lillian L. Siu, Jeffrey R. Infante, S. Martin Shreeve, W. Gregory Roberts, Huiping Xu, Suzanne McDermott, Howard A. Burris, Geoffrey I. Shapiro and Johanna C. Bendell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Kristen J. Pierce

31 papers receiving 992 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kristen J. Pierce United States	14	524	350	209	183	143	33	1.0k
Stacey DaCosta Byfield United States	13	753 1.4×	579 1.7×	213 1.0×	55 0.3×	65 0.5×	51	1.5k
Christian Kurzeder Germany	25	363 0.7×	709 2.0×	225 1.1×	69 0.4×	57 0.4×	88	2.0k
Terukazu Nakamura Japan	19	568 1.1×	348 1.0×	368 1.8×	60 0.3×	25 0.2×	70	1.3k
Melanie J. McCoy Australia	16	218 0.4×	323 0.9×	164 0.8×	126 0.7×	40 0.3×	28	1.0k
Teresa Helsten United States	15	658 1.3×	440 1.3×	355 1.7×	43 0.2×	75 0.5×	31	1.2k
Arto Leminen Finland	28	415 0.8×	538 1.5×	256 1.2×	49 0.3×	82 0.6×	60	1.9k
Riccardo Roagna Italy	15	290 0.6×	393 1.1×	236 1.1×	58 0.3×	20 0.1×	26	962
Sharon B. Chang United States	10	539 1.0×	365 1.0×	61 0.3×	116 0.6×	101 0.7×	23	986
Gregor Eisenwort Austria	20	303 0.6×	246 0.7×	64 0.3×	71 0.4×	38 0.3×	54	1.0k
Håkon Wæhre Norway	22	438 0.8×	385 1.1×	552 2.6×	23 0.1×	84 0.6×	47	1.4k

Countries citing papers authored by Kristen J. Pierce

Since Specialization

Citations

This map shows the geographic impact of Kristen J. Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristen J. Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristen J. Pierce more than expected).

Fields of papers citing papers by Kristen J. Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristen J. Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristen J. Pierce. The network helps show where Kristen J. Pierce may publish in the future.

Co-authorship network of co-authors of Kristen J. Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Kristen J. Pierce. A scholar is included among the top collaborators of Kristen J. Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristen J. Pierce. Kristen J. Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

King, Jasmine, et al.. (2025). Evaluating Pharmacotherapy Optimization in Pharmacist-Led Management of Type 2 Diabetes Utilizing Continuous Glucose Monitors. Journal of Primary Care & Community Health. 16. 2982955–2982955.

Shore, Neal D., Thomas Powles, Jens Bedke, et al.. (2022). A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B.. Journal of Clinical Oncology. 40(16_suppl). TPS4614–TPS4614. 2 indexed citations

Curigliano, Giuseppe, Geoffrey I. Shapiro, Rebecca Kristeleit, et al.. (2022). A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British Journal of Cancer. 128(1). 30–41. 24 indexed citations

Wang, Eunice S., Richard Aplenc, Deborah Chirnomas, et al.. (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 61(8). 1965–1973. 11 indexed citations

Forero‐Torres, Andres, Heather Han, Elizabeth Claire Dees, et al.. (2018). Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).. Journal of Clinical Oncology. 36(15_suppl). 1040–1040. 12 indexed citations

Wang, Eunice S., Richard Aplenc, Deborah Chirnomas, et al.. (2018). Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 3979–3979. 1 indexed citations

Wainberg, Zev A., María Alsina, Heloisa P. Soares, et al.. (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted Oncology. 12(6). 775–785. 79 indexed citations

Campo, Josep M. del, Michael J. Birrer, Craig B. Davis, et al.. (2016). A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology. 142(1). 62–69. 82 indexed citations

Shapiro, Geoffrey I., Katherine M. Bell‐McGuinn, Julian R. Molina, et al.. (2015). First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clinical Cancer Research. 21(8). 1888–1895. 97 indexed citations

10.

Jones, Suzanne F., Lillian L. Siu, Johanna C. Bendell, et al.. (2015). A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 33(5). 1100–1107. 125 indexed citations

11.

Wainberg, Zev A., Geoffrey I. Shapiro, Giuseppe Curigliano, et al.. (2015). Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.. Journal of Clinical Oncology. 33(15_suppl). 2590–2590. 3 indexed citations

12.

Wainberg, Zev A., Nicoletta Brega, Craig B. Davis, et al.. (2014). Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007; NCT01937715).. Journal of Clinical Oncology. 32(15_suppl). TPS3657–TPS3657. 3 indexed citations

13.

Britten, Carolyn D., Alex A. Adjei, Robert Millham, et al.. (2014). Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Investigational New Drugs. 32(3). 510–517. 66 indexed citations

14.

Infante, Jeffrey R., D. Ross Camidge, Linda Mileshkin, et al.. (2012). Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. Journal of Clinical Oncology. 30(13). 1527–1533. 195 indexed citations

15.

Schöffski, Patrick, Suzanne F. Jones, Herlinde Dumez, et al.. (2011). Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer. 47(15). 2256–2264. 49 indexed citations

16.

Jones, Suzanne F., Geoffrey I. Shapiro, Johanna C. Bendell, et al.. (2011). Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3002–3002. 10 indexed citations

17.

Vlahovic, Gordana, et al.. (2010). Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. British Journal of Cancer. 103(10). 1554–1561. 15 indexed citations

18.

Lewis, Nancy, et al.. (2007). Phase 1 study of CP-868,596 an oral, highly specific PDGFR inhibitor. Journal of Clinical Oncology. 25(18_suppl). 3524–3524. 2 indexed citations

19.

Ewing, Gary B., et al.. (2004). Evaluation of a Cardiovascular Health Program for Participants with Mental Retardation and Normal Learners. Health Education & Behavior. 31(1). 77–87. 61 indexed citations

20.

Pierce, Kristen J., et al.. (2003). Predictors of job tenure for new hires with mental retardation. Research in Developmental Disabilities. 24(5). 369–380. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact